ARPA-H grants funding to biotech firms developing custom RNA therapies amid broader biotech updates

ARPA-H is providing grants to several biotech companies to develop custom RNA therapeutics, aiming to accelerate personalized medicine.

Roche has licensed a tri‑specific antibody, adding a new modality to its pipeline.

UniQure has submitted applications to the FDA and the UK’s MHRA for its Huntington’s disease gene therapy, AMT‑130, seeking marketing approval.

President Trump highlighted recent deals with biopharma companies intended to lower drug costs, but analysts argue the agreements may have limited effect and could even conflict with the administration’s broader cost‑reduction goals.